Calidi Biotherapeutics, Inc. CLDI
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2021 · data as of November 13, 2026
Calidi Biotherapeutics, Inc. (CLDI) is a healthcare company listed in the US with a market value of about $2M.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is value (2/5); the weakest is future growth (0/5).
Key numbers: a P/E of 0.0, a 5-year average ROIC of -243%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 99% below the current price.
About Calidi Biotherapeutics
Calidi Biotherapeutics is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2021. It was profitable in 0 of the last 4 years in our data. Its share count rose by 5980% over three years (dilution for shareholders).
Score: 0.8 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
Valuation
Growth and quality
Financials, last 4 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | — | — | — | $45000 |
| Net income | -$20M | -$22M | -$29M | -$25M |
| Free cash flow | — | — | — | — |
| EPS (diluted) | $-5.95 | $-35.70 | $-207985.98 | $359419.49 |
| Net margin | — | — | — | -56504.4% |
| ROIC | -264.7% | -220.4% | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
What is Calidi Biotherapeutics’s P/E ratio?
About 0.0, based on the last twelve months of diluted earnings per share.
Is Calidi Biotherapeutics stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 99% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Calidi Biotherapeutics pay a dividend?
Not currently.
Is Calidi Biotherapeutics a good stock to buy?
We do not give buy or sell advice. Calidi Biotherapeutics scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.